Jose M Medina is a notable inventor based in Thousand Oaks, California. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that target specific cancer-related proteins. With a total of 2 patents to his name, Medina's work is paving the way for new treatment options for various types of cancer.

Latest Patents

Medina's latest patents include innovative compounds that act as inhibitors of the G12C mutant KRAS protein. The first patent details heterocyclic spiro compounds and methods of use, which provide pharmaceutical compositions aimed at treating disorders such as lung, pancreatic, and colorectal cancers. The second patent reiterates the same compounds and their applications, emphasizing their potential in cancer treatment.

Career Highlights

Throughout his career, Medina has been associated with Amgen Inc., a leading biotechnology company. His work at Amgen has allowed him to focus on groundbreaking research that addresses critical health challenges. His contributions are not only significant in terms of patent numbers but also in their potential impact on patient care.

Collaborations

Medina has collaborated with talented individuals such as Vu Van Ma and Francesco Manoni. These partnerships have fostered an environment of innovation and creativity, further enhancing the quality of research and development in which he is involved.

Conclusion

Jose M Medina's work exemplifies the spirit of innovation in the pharmaceutical industry. His patents and collaborations reflect a commitment to advancing cancer treatment options, making a meaningful difference in the lives of patients.

Profile summary based on public USPTO records.